Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT06248242

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06248242
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06248242. Randomized; double masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol
Acronym
TASPE
Condition
Acute Ischemic Stroke
Intervention (Drug)
Edaravone dexborneol
Lead sponsor
The Second Hospital of Hebei Medical University (class: other)

Record details

Record id
cardio:ct-nct06248242
Content hash
c5230e3210b0c2956e8f5cadf372cab99c426032068802b701e351519a9ce083